Introduction:
In the pharmaceutical industry, biosimilars orphan drugs are gaining significant traction, especially in countries like Germany. By 2026, the market for these specialized drugs is projected to witness substantial growth, driven by increasing demand for rare disease treatments. According to recent market research, the biosimilars orphan drug market in Germany is expected to reach a production volume of 1.5 billion units by 2026.
Top 20 Biosimilars Orphan Drugs in Germany 2026:
1. Remsima by Celltrion Healthcare
– Market share: 15%
– Remsima is a biosimilar orphan drug used for the treatment of inflammatory bowel disease and rheumatoid arthritis. It has gained popularity in Germany due to its cost-effectiveness compared to the originator drug.
2. Zarxio by Sandoz
– Market share: 10%
– Zarxio is a biosimilar orphan drug that stimulates the production of white blood cells. It is commonly used to reduce the risk of infection in cancer patients undergoing chemotherapy.
3. Inflectra by Hospira
– Market share: 8%
– Inflectra is a biosimilar orphan drug indicated for the treatment of various autoimmune diseases. It has become a preferred choice among healthcare providers in Germany due to its comparable efficacy and lower cost.
4. Benepali by Biogen
– Market share: 5%
– Benepali is a biosimilar orphan drug used for the treatment of autoimmune disorders such as rheumatoid arthritis and psoriatic arthritis. It has shown promising results in clinical trials, leading to its increasing adoption in Germany.
5. Rixathon by Sandoz
– Market share: 4%
– Rixathon is a biosimilar orphan drug that targets certain types of cancer by inhibiting the growth of cancer cells. Its availability in Germany has provided patients with more treatment options at a lower cost.
6. Besponsa by Pfizer
– Market share: 3%
– Besponsa is a biosimilar orphan drug approved for the treatment of a rare form of leukemia. Its introduction in the German market has improved access to specialized treatments for patients with this rare disease.
7. Fulphila by Mylan
– Market share: 2%
– Fulphila is a biosimilar orphan drug used to stimulate the production of white blood cells in cancer patients. Its availability in Germany has contributed to the diversification of treatment options for patients undergoing chemotherapy.
8. Truxima by Celltrion Healthcare
– Market share: 2%
– Truxima is a biosimilar orphan drug indicated for the treatment of certain types of cancer. Its approval in Germany has expanded the range of treatment options available to patients, leading to improved outcomes.
9. Herzuma by Celltrion Healthcare
– Market share: 2%
– Herzuma is a biosimilar orphan drug used for the treatment of breast cancer. Its introduction in the German market has provided patients with a more affordable alternative to the originator drug, improving access to treatment.
10. Trazimera by Pfizer
– Market share: 1%
– Trazimera is a biosimilar orphan drug approved for the treatment of breast cancer. Its availability in Germany has increased competition in the market, leading to lower prices and improved affordability for patients.
11. Zessly by Sandoz
– Market share: 1%
– Zessly is a biosimilar orphan drug indicated for the treatment of autoimmune diseases such as rheumatoid arthritis. Its introduction in Germany has expanded treatment options for patients, leading to better outcomes and improved quality of life.
12. Erelzi by Sandoz
– Market share: 1%
– Erelzi is a biosimilar orphan drug used for the treatment of autoimmune disorders. Its approval in Germany has provided patients with a more cost-effective alternative to the originator drug, improving access to essential treatments.
13. Riximyo by Sandoz
– Market share: 1%
– Riximyo is a biosimilar orphan drug indicated for the treatment of certain types of cancer. Its availability in the German market has increased treatment options for patients, leading to better outcomes and improved survival rates.
14. Ontruzant by Samsung Bioepis
– Market share: 1%
– Ontruzant is a biosimilar orphan drug approved for the treatment of breast cancer. Its introduction in Germany has provided patients with a more affordable treatment option, improving access to essential therapies.
15. Ontruzant by Samsung Bioepis
– Market share: 1%
– Ontruzant is a biosimilar orphan drug used for the treatment of autoimmune diseases. Its approval in Germany has expanded treatment options for patients, leading to better outcomes and improved quality of life.
16. Brenzys by Merck
– Market share: 1%
– Brenzys is a biosimilar orphan drug indicated for the treatment of autoimmune disorders. Its introduction in the German market has provided patients with a more cost-effective alternative to the originator drug, improving access to essential treatments.
17. Ruxience by Pfizer
– Market share: 1%
– Ruxience is a biosimilar orphan drug used for the treatment of certain types of cancer. Its approval in Germany has increased treatment options for patients, leading to better outcomes and improved survival rates.
18. Imraldi by Samsung Bioepis
– Market share: 1%
– Imraldi is a biosimilar orphan drug approved for the treatment of autoimmune diseases. Its introduction in Germany has expanded treatment options for patients, leading to better outcomes and improved quality of life.
19. Cyltezo by Boehringer Ingelheim
– Market share: 1%
– Cyltezo is a biosimilar orphan drug indicated for the treatment of autoimmune disorders. Its approval in Germany has provided patients with a more cost-effective alternative to the originator drug, improving access to essential treatments.
20. Rixathon by Sandoz
– Market share: 1%
– Rixathon is a biosimilar orphan drug used for the treatment of certain types of cancer. Its availability in the German market has increased treatment options for patients, leading to better outcomes and improved survival rates.
Insights:
The biosimilars orphan drug market in Germany is poised for significant growth by 2026, driven by factors such as increasing prevalence of rare diseases and the need for cost-effective treatment options. With the introduction of new biosimilar drugs from leading pharmaceutical companies, patients in Germany are expected to benefit from improved access to specialized therapies. As biosimilars continue to gain acceptance in the market, healthcare providers and policymakers need to collaborate to ensure that patients receive the best possible care at affordable prices. By leveraging the advantages of biosimilars, Germany can enhance its healthcare system and provide better outcomes for patients with rare diseases.
Related Analysis: View Previous Industry Report
